Table 2.

CAR T-cell–associated adverse events

EventAny, n (%)Severe (grade 3/4) n (%)
CRS 20 (80) 4 (16) 
Tachycardia 15 (60) 
Hypertension 5 (20) 1 (4) 
Cardiac dysfunction/arrhythmia 1 (4) 1 (4) 
Cytopenia   
 Neutropenia 3 (12) 3 (12) 
 Thrombocytopenia 4 (16) 4 (16) 
Infection 9 (36) 6 (24) 
CAR T-cell–associated neurotoxicity 18 (72) 7 (28) 
Headache 5 (20) 1 (8) 
Tremor or hyperreflexia/clonus 7 (28) 
Altered mental status* 12 (48) 5 (20) 
Seizure (clinical or abnormal EEG) 5 (20) 5 (20) 
Involuntary movements 1 (8) 
Ataxia 1 (8) 
EventAny, n (%)Severe (grade 3/4) n (%)
CRS 20 (80) 4 (16) 
Tachycardia 15 (60) 
Hypertension 5 (20) 1 (4) 
Cardiac dysfunction/arrhythmia 1 (4) 1 (4) 
Cytopenia   
 Neutropenia 3 (12) 3 (12) 
 Thrombocytopenia 4 (16) 4 (16) 
Infection 9 (36) 6 (24) 
CAR T-cell–associated neurotoxicity 18 (72) 7 (28) 
Headache 5 (20) 1 (8) 
Tremor or hyperreflexia/clonus 7 (28) 
Altered mental status* 12 (48) 5 (20) 
Seizure (clinical or abnormal EEG) 5 (20) 5 (20) 
Involuntary movements 1 (8) 
Ataxia 1 (8) 

Adverse events were captured for all treated patients (n = 25) until disease relapse, application of alternative therapy, or death. CRS was graded according to the NCI consensus CRS grading system. CRS symptoms include fever, which occurred in 68% (17/25), hypotension in 44% (11/25), and hypoxia in 12% (3/25) of patients. ASTCT CRS consensus grading (fever a required element) occurred in 68% (17/25) of patients, including a sCRS rate of 16% (4/25) of patients. CAR T-cell–associated neurotoxicity included any neurologic sequalae following the infusion of CAR T cells. EEG, electroencephalogram.

*

Altered mental status included somnolence, depressed level of consciousness, confusion, slurred speech, cognitive disturbance, delirium, and/or personality change.

Seizure included clinically apparent seizure or electroencephalogram findings consistent with seizure.

Close Modal

or Create an Account

Close Modal
Close Modal